1H-苯并[d][1,2,3]噻唑-5-甲醛 | 70938-42-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: 1H-苯并[d][1,2,3]噻唑-5-甲醛
• 英文名称: 1H-benzo[d][1,2,3]triazole-5-carbaldehyde
• 英文别名: 2H-benzotriazole-5-carbaldehyde
• CAS: 70938-42-0
• 化学式: C₇H₅N₃O
• 分子量: 147.136
• InChiKey: GJBWJHRJXRTAIC-UHFFFAOYSA-N

物化性质

• 沸点：
  448.9±18.0 °C(Predicted)
• 密度：
  1.471±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1H-苯并[d][1,2,3]噻唑-5-甲醛 在 palladium on activated charcoal 盐酸 、 盐酸羟胺 、 氢气 、 sodium acetate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 1-(1H-Benzotriazol-5-ylmethyl)-3-(4-tert-butyl-benzyl)-thiourea
  参考文献：
  名称：

  Novel Potent Antagonists of Transient Receptor Potential Channel, Vanilloid Subfamily Member 1:  Structure−Activity Relationship of 1,3-Diarylalkyl Thioureas Possessing New Vanilloid Equivalents

  摘要：

  Recently, 1,3-diarylalkyl thioureas have merged as one of the promising nonvanilloid TRPV1 antagonists possessing excellent therapeutic potential in pain regulation. In this paper, the full structure-activity relationship for TRPV1 antagonism of a novel series of 1,3-diarylalky thioureas is reported. Exploration of the structure- activity relationship, by systemically modulating three essential pharmacophoric regions, led to six examples of 1,3-dibenzyl thioureas, which exhibit Ca2+ uptake inhibition in rat DRG neuron with IC50 between 10 and 100 nM.

  DOI：

  10.1021/jm0502790
• 作为产物：
  描述：

  1,2,3-苯并三唑-5-羧酸甲酯 在 lithium aluminium tetrahydride 、 重铬酸吡啶 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 8.0h， 生成 1H-苯并[d][1,2,3]噻唑-5-甲醛
  参考文献：
  名称：

  Synthesis and Practical Use of 1H‐1,2,3‐Benzotriazole‐5‐carboxaldehyde for Reductive Amination

  摘要：

  A reliable synthetic procedure to obtain multigram quantities of 1H-1,2,3-benzotriazole-5-carboxaldehyde has been developed. This material can be used in reductive amination reactions with primary and secondary amines to provide good to excellent yields of the desired products without protection of the starting material.

  DOI：

  10.1080/00397910500214151

文献信息

• Substituted Pyran Derivatives
  申请人：Wayne State University

  公开号：US20140309427A1

  公开（公告）日：2014-10-16

  Certain 3,6-disubstituted and 2, 4, 5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3, 6 and 2, 4, 5 pyrans are useful in probing the effects of their binding to monoamine transporter systems and the corresponding relationships to various afflictions affecting the CNS, or as a treatment for various CNS-related disorders in which the monoamine transport and related systems are implicated.

  提供了在单胺转运系统上表现出强效活性的某些3,6-二取代和2,4,5-三取代吡喃衍生物。这些3,6和2,4,5吡喃物在探究它们与单胺转运体系的结合效应以及与影响中枢神经系统的各种疾病之间的关系，或作为治疗涉及单胺转运和相关系统的各种中枢神经系统相关疾病的方法中是有用的。
• SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
  申请人：Bignan Gilles

  公开号：US20110294780A1

  公开（公告）日：2011-12-01

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），与骨相关的疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丧失，软骨退化以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性腰部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态紊乱，痛风，假性痛风，脂质紊乱，代谢综合征，多发性骨髓瘤，肥胖，骨关节炎，遗传性骨发育不全，骨溶解性骨转移，软骨软化症，骨质疏松症，帕金森病，牙周病，多肌痛风，Reiter综合征，重复性应激损伤，高血糖，血糖水平升高和胰岛素抵抗等病症的方法。
• [EN] NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES<br/>[FR] NOUVEAUX DÉRIVÉS HÉTÉROCYCLIQUES AYANT UNE ACTIVITÉ DE PROLIFÉRATION DE CARDIOMYOCYTES POUR LE TRAITEMENT DE MALADIES CARDIAQUES
  申请人：UNIV TONGJI

  公开号：WO2021115489A1

  公开（公告）日：2021-06-17

  Provided are novel heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases. Specifically, provided are the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method thereof, application thereof and pharmaceutical composition useful for treatment of heart diseases.

  提供了具有心肌细胞增殖活性的新型杂环衍生物，用于治疗心脏疾病。具体提供了式（I）的化合物或药用盐、立体异构体、溶剂合物或前药，其制备方法、应用以及用于治疗心脏疾病的药物组合物。
• [EN] ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DERIVES D'ANABASEINE UTILES POUR LE TRAITEMENT DE MALADIES NEURODEGENERATIVES
  申请人：MEMORY PHARM CORP

  公开号：WO2004019943A1

  公开（公告）日：2004-03-11

  The compounds of the present invention are of formula (I): wherein A, R3, R4 is as defined herein, are useful as ligands for nicotinic receptors.

  本发明的化合物的化学式为（I）：其中A、R3、R4如本文所定义，可用作尼古丁受体的配体。
• [EN] COMPOUNDS AND METHODS OF MODULATING 17β-ΗYDROXYSTEROID DEHYDROGENASE TYPE 13<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DE LA 17β-ΗYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 13
  申请人：METREA BIOSCIENCES INC

  公开号：WO2022040324A1

  公开（公告）日：2022-02-24

  The present disclosure is generally directed to modulators of hydroxysteroid dehydrogenase enzymes useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), Formula (II), or Formula (III).

  本公开涉及一般指向对羟基甾醇脱氢酶酶的调节剂，用于治疗受该酶调节的疾病和疾病，并具有化学式（I）、化学式（II）或化学式（III）。